Second Sight Announces Positive Long-Term Results of the Argus II Retinal Prosthesis System

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today announced positive three year results post-implant of its Argus® II Retinal Prosthesis System (“Argus II”) from a multi-center clinical trial. The paper titled, “Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind”, highlights